P. Keeling

发表

Driving personalized medicine: capturing maximum net present value and optimal return on investment.

Mollie Roth, P. Keeling, D. Smart, 2010, Personalized medicine.

Challenges in the clinical implementation of precision medicine companion diagnostics

Jordan Clark, P. Keeling, S. Finucane, 2020, Expert review of molecular diagnostics.

Infusion medication concentrations in UK’s critical care areas: Are the Intensive Care Society’s recommendations being used?

P. Keeling, M. Borthwick, Yovita D Titiesari, 2017, Journal of the Intensive Care Society.

Cost‐effectiveness of precision diagnostic testing for precision medicine approaches against non‐small‐cell lung cancer: A systematic review

M. Lawler, R. Sullivan, P. Keeling, 2021, Molecular oncology.

A modelling study of once-bred heifer beef production

D. I. Gray, P. C. B. Keeling, S. T. Morris, 1991 .

A Survey to Inform Standardisation of Intravenous Medication Concentrations in Critical Care

C. Waldmann, P. Keeling, M. Borthwick, 2007 .

Towards a balanced value business model for personalized medicine: an outlook.

P. Keeling, J. Przewrocka, Christof Koelsch, 2013, Pharmacogenomics.

Industry engagement: Accelerating discovery, application, and adoption through industry partnerships

J. Ofman, P. Keeling, S. Finucane, 2022, Cancer.

Towards IV drug standardization in critical care.

P. Keeling, M. Borthwick, K. Scales, 2010, British journal of nursing.

The economics of personalized medicine: commercialization as a driver of return on investment.

Mollie Roth, P. Keeling, Tom Zietlow, 2012, New biotechnology.

Towards Standardisation of Drug Infusion Concentrations in UK Critical Care Units

C. Waldmann, P. Keeling, M. Borthwick, 2009 .